The U.S. Food and Drug Administration has approved Padcev (enfortumab vedotin-ejfv) combined with Keytruda (pembrolizumab) as neoadjuvant and adjuvant treatment ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE